Advertisement
Screener

CRYOPORT, INC. (CYRX) Induced Conversion of Convertible Debt Expense

3.1 / 5 stars · 51/81 Roast Me

CRYOPORT, INC. Induced Conversion of Convertible Debt Expense

CRYOPORT, INC. (CYRX) reported Induced Conversion of Convertible Debt Expense of $0 for the 12-month period ending 2015-03-31, per its 10-K filed 2015-05-19.

Discontinued › Expense Statement › Operating Expenses

us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2015-05-19

  • CRYOPORT, INC. induced conversion of convertible debt expense for the quarter ending 2015-03-31 was $0.00.
  • CRYOPORT, INC. induced conversion of convertible debt expense for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
  • CRYOPORT, INC. induced conversion of convertible debt expense for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
  • CRYOPORT, INC. induced conversion of convertible debt expense for the quarter ending 2014-06-30 was $0.00.
  • CRYOPORT, INC. induced conversion of convertible debt expense for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
  • CRYOPORT, INC. induced conversion of convertible debt expense for fiscal 2014 was $13.71M.
Period endInduced Conversion of Convertible Debt Expense 2 monthInduced Conversion of Convertible Debt Expense 3 monthInduced Conversion of Convertible Debt Expense 6 monthInduced Conversion of Convertible Debt Expense 9 monthInduced Conversion of Convertible Debt Expense 12 month
2015-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19
$0.00
derived: sum of 2 quarters · filed 2015-05-19
$0.00
derived: sum of 3 quarters · filed 2015-05-19
$0.00
10-K · filed 2015-05-19
2014-12-31$0.00
10-Q · filed 2015-02-05
$0.00
derived: sum of 2 quarters · filed 2015-02-05
$0.00
10-Q · filed 2015-02-05
$0.00
derived: sum of 4 quarters · filed 2015-05-19
2014-09-30$0.00
10-Q · filed 2014-11-12
$0.00
10-Q · filed 2014-11-12
$0.00
derived: sum of 3 quarters · filed 2015-05-19
$552.75K
derived: sum of 4 quarters · filed 2015-05-19
2014-06-30$0.00
derived: 10-K 12 month − 3 quarters · filed 2015-05-19
$0.00
derived: sum of 2 quarters · filed 2015-05-19
$552.75K
derived: sum of 3 quarters · filed 2015-05-19
$13.71M
derived: sum of 4 quarters · filed 2015-05-19
2014-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19
$552.75K
derived: sum of 2 quarters · filed 2015-05-19
$13.71M
derived: sum of 3 quarters · filed 2015-05-19
$13.71M
10-K · filed 2015-05-19
2013-12-31$552.75K
10-Q · filed 2015-02-05
$13.71M
derived: sum of 2 quarters · filed 2015-02-05
$13.71M
10-Q · filed 2015-02-05
2013-10-31$13.71M
10-Q · filed 2014-02-13
2013-09-30$13.16M
10-Q · filed 2014-11-12
$13.16M
10-Q · filed 2014-11-12
2012-12-31$0.00
10-Q · filed 2014-02-13
$0.00
derived: sum of 2 quarters · filed 2014-02-13
$0.00
10-Q · filed 2014-02-13
2012-09-30$0.00
10-Q · filed 2013-11-18
$0.00
10-Q · filed 2013-11-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Apnimed, Inc. (APMD)United States$0.899B
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71